KR20210135261A - 인플루엔자 ha 스플릿 백신의 제조 방법 - Google Patents

인플루엔자 ha 스플릿 백신의 제조 방법 Download PDF

Info

Publication number
KR20210135261A
KR20210135261A KR1020217030986A KR20217030986A KR20210135261A KR 20210135261 A KR20210135261 A KR 20210135261A KR 1020217030986 A KR1020217030986 A KR 1020217030986A KR 20217030986 A KR20217030986 A KR 20217030986A KR 20210135261 A KR20210135261 A KR 20210135261A
Authority
KR
South Korea
Prior art keywords
influenza
split vaccine
vaccine
split
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217030986A
Other languages
English (en)
Korean (ko)
Inventor
요시마사 다카하시
유 아다치
마나부 아토
Original Assignee
국립감염증연구소장이 대표하는 일본국
다이닛본 스미토모 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 국립감염증연구소장이 대표하는 일본국, 다이닛본 스미토모 세이야꾸 가부시끼가이샤 filed Critical 국립감염증연구소장이 대표하는 일본국
Publication of KR20210135261A publication Critical patent/KR20210135261A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020217030986A 2019-03-04 2020-03-03 인플루엔자 ha 스플릿 백신의 제조 방법 Pending KR20210135261A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2019-038662 2019-03-04
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (1)

Publication Number Publication Date
KR20210135261A true KR20210135261A (ko) 2021-11-12

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030986A Pending KR20210135261A (ko) 2019-03-04 2020-03-03 인플루엔자 ha 스플릿 백신의 제조 방법

Country Status (15)

Country Link
US (1) US12491240B2 (https=)
EP (1) EP3936147A4 (https=)
JP (1) JP7545955B2 (https=)
KR (1) KR20210135261A (https=)
CN (1) CN114096273B (https=)
AU (1) AU2020233456B2 (https=)
BR (1) BR112021017310A8 (https=)
CA (1) CA3132578A1 (https=)
EA (1) EA202192398A1 (https=)
IL (1) IL285984A (https=)
MX (1) MX2021010685A (https=)
MY (1) MY208974A (https=)
PH (1) PH12021552094A1 (https=)
SG (1) SG11202109566XA (https=)
WO (1) WO2020179797A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
MX2022005513A (es) * 2019-11-07 2022-06-08 Seqirus Uk Ltd Composiciones y metodos para producir una vacuna viral con tama?o de particula reducido.
EP4703377A1 (en) 2023-04-26 2026-03-04 Japan Institute for Health Security Anti-influenza antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516090A (ja) 2013-03-29 2016-06-02 セルトリオン・インコーポレイテッド ２以上のインフルエンザａウイルス中和結合分子を含む組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009115917A2 (en) * 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
WO2010010467A2 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
US8815252B2 (en) * 2008-11-25 2014-08-26 Baxter Healthcare Sa Method for production of pH stable enveloped viruses
CN101524538A (zh) 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011111966A2 (en) 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CN103502263A (zh) 2011-04-21 2014-01-08 巴克斯特国际公司 用于从疫苗离析和量化抗原的方法
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
CN106794241A (zh) 2014-08-18 2017-05-31 圣诺菲·帕斯图尔公司 烷基化流感疫苗
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
PL3603619T3 (pl) * 2017-03-29 2025-11-17 Sumitomo Pharma Co., Ltd. Preparat adjuwantu szczepionkowego
MY204177A (en) * 2017-09-04 2024-08-14 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for producing influenza ha split vaccine
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CA3107409A1 (en) * 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CN113194986A (zh) * 2018-12-26 2021-07-30 大日本住友制药株式会社 包括疫苗佐剂的制剂
WO2020176524A1 (en) * 2019-02-28 2020-09-03 Novavax, Inc. Methods for preventing disease or disorder caused by rsv infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516090A (ja) 2013-03-29 2016-06-02 セルトリオン・インコーポレイテッド ２以上のインフルエンザａウイルス中和結合分子を含む組成物

Also Published As

Publication number Publication date
CA3132578A1 (en) 2020-09-10
WO2020179797A1 (ja) 2020-09-10
US20220152191A1 (en) 2022-05-19
AU2020233456A1 (en) 2021-10-07
MY208974A (en) 2025-06-14
EP3936147A4 (en) 2022-09-28
MX2021010685A (es) 2021-12-10
EA202192398A1 (ru) 2021-11-23
PH12021552094A1 (en) 2022-05-30
IL285984A (en) 2021-10-31
JPWO2020179797A1 (https=) 2020-09-10
CN114096273A (zh) 2022-02-25
JP7545955B2 (ja) 2024-09-05
BR112021017310A2 (https=) 2021-11-16
BR112021017310A8 (pt) 2022-12-06
AU2020233456B2 (en) 2026-04-09
US12491240B2 (en) 2025-12-09
SG11202109566XA (en) 2021-10-28
CN114096273B (zh) 2026-03-17
EP3936147A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
US9511134B2 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
KR102733152B1 (ko) 인플루엔자 ha 스플릿 백신의 제조 방법
KR20210135261A (ko) 인플루엔자 ha 스플릿 백신의 제조 방법
US20230406910A1 (en) Method for producing influenza ha split vaccine
JP2023052092A (ja) 免疫原性組成物
EP2307036A1 (en) Novel peptide adjuvant for influenza vaccination
US10195266B2 (en) Versatile influenza virus vaccine composition
Wen et al. A novel M2e-multiple antigenic peptide providing heterologous protection in mice
TWI857017B (zh) 流感ha裂解疫苗之製造方法
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
KR101768600B1 (ko) 범용성 개 인플루엔자 바이러스 백신 조성물
HK40068192A (en) Method for preparing influenza ha split vaccine
HK40032891A (en) Method for producing influenza ha split vaccine
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
CN111163801A (zh) 用于流感病毒的基于乙型肝炎纳米颗粒的疫苗
Jiang et al. Feng Wen, Ji-Hong Ma, Hai Yu*, Fu-Ru Yang, Meng Huang, Yan-Jun Zhou, Ze-Jun Li, Xiu-Hui Wang, Guo-Xin Li
Wen Feng et al. A novel M2e-multiple antigenic peptide providing heterologous protection in mice.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000